文献速递肝病

MASLD组织学进展与逆转的遗传及非遗传驱动因素

Genetic and non-genetic drivers of histological progression and regression in MASLD.
PubMed 文献 · J Hepatol · 2025-09-24

该研究纳入671例(444成人、227儿童)有≥2次肝活检的MASLD患者,分析PNPLA3、TM6SF2和HSD17B13三个SNP与组织学纵向变化的关系。PNPLA3 G等位基因增加纤维化进展风险,HSD17B13 A等位基因减轻进展并促进逆转,3-SNP多基因风险评分可预测进展与逆转,且受年龄、性别、BMI和T2DM修饰。

要点

  • PNPLA3 G等位基因增加纤维化进展风险(aHR 1.31)。
  • HSD17B13 A等位基因降低进展并增加MASH缓解和纤维化逆转。
  • 3-SNP多基因风险评分可独立预测组织学进展与逆转。

核心结论

  • 遗传易感性及其与非遗传因素的显著交互作用驱动MASLD组织学的动态轨迹。
  • 研究为个体化风险分层和管理提供了关键框架。

研究设计与样本

  • 分析671例(444成人、227儿童)来自不同NASH CRN研究和随机对照试验、有≥2次连续肝活检的个体。
  • 采用区间删失Cox模型,校正种族/民族、性别、年龄、BMI、2型糖尿病和研究聚类。

主要发现

  • PNPLA3 G等位基因增加纤维化进展风险(aHR 1.31,95%CI 1.05-1.64)。
  • HSD17B13 A等位基因降低MASL向MASH进展风险(aHR 0.46,95%CI 1.5-3.9)和纤维化进展风险(aHR 0.69,95%CI 0.51-0.92)。
  • HSD17B13 A等位基因增加MASH缓解可能性(aHR 1.58,95%CI 1.13-2.22)和纤维化逆转可能性(aHR 1.42,95%CI 1.09-1.85)。
  • TM6SF2 T等位基因未影响组织学变化。
  • 3-SNP多基因风险评分(风险等位基因之和)与MASL向MASH进展风险(aHR 1.33,95%CI 1.03-1.71)和纤维化进展风险(aHR 1.37,95%CI 1.18-1.60)增加相关。

关键数值与推荐

  • PNPLA3 rs738409、TM6SF2 rs58542926和HSD17B13 rs72613567为分析的三个SNP。
  • 非遗传因素包括T2DM和BMI变化也独立影响组织学。
  • 单变异和多基因风险评分的效应受年龄、性别、BMI和T2DM显著修饰。

临床怎么用

  • 可考虑将PNPLA3、HSD17B13和TM6SF2基因变异及多基因风险评分用于MASLD个体化风险分层。
  • 管理策略需综合考虑遗传变异与非遗传因素(如T2DM、BMI变化)的交互作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The association between genetic variants and longitudinal changes in liver histology has not been well characterized. We examined relationships between three single nucleotide polymorphisms (SNPs) - PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs72613567 - and longitudinal changes in liver histology. METHODS: A total of 671 (444 adults and 227 children) individuals enrolled in different NASH CRN studies and randomized controlled trials, with ≥2 serial liver biopsies, were analyzed. The main outcomes were progression from metabolic dysfunction-associated steatotic liver (MASL) to steatohepatitis (MASH), ≥1 stage increase in fibrosis, and resolution of MASH or fibrosis regression ≥1 stage. Interval-censored Cox models, adjusted for race/ethnicity, sex, age, BMI, type 2 diabetes mellitus (T2DM), and study cluster, were used to examine the associations between genetic variants and histological outcomes. RESULTS: The PNPLA3 G allele increased the risk of fibrosis progression (adjusted hazard ratio [aHR] 1.31, 95% CI 1.05-1.64). The HSD17B13 A allele attenuated MASL to MASH progression (aHR 0.46, 95% CI 1.5-3.9) and fibrosis progression (aHR 0.69, 95% CI 0.51-0.92) while increasing the likelihood of MASH resolution (aHR 1.58, 95% CI 1.13-2.22) and fibrosis regression (aHR 1.42, 95% CI 1.09-1.85). The TM6SF2 T allele did not influence histological changes. An unweighted 3-SNP polygenic risk score, incorporating PNPLA3, HSD17B13, and TM6SF2 risk alleles, was associated with an increased risk of MASL to MASH progression (aHR 1.33, 95% CI 1.03-1.71) and fibrosis progression (aHR 1.37, 95% CI 1.18-1.60). The unweighted sum of the 3-SNP non-risk alleles was associated with a higher chance of MASH resolution (aHR 1.21, 95% CI 1.02-1.43). Non-genetic factors, including T2DM and BMI change, also independently influenced histology. The effects of single variants and the PRS were significantly modified by age, sex, BMI, and T2DM. CONCLUSION: Genetic predisposition and its significant interactions with non-genetic factors drive the dynamic trajectory of MASLD, providing a critical framework for personalized risk stratification and management. IMPACT AND IMPLICATIONS: Histological changes in metabolic dysfunction-associated steatotic liver disease are driven by complex interactions between genetic and non-genetic factors, not by isolated influences. The PNPLA3 rs738409 allele worsened fibrosis and steatosis, while the HSD17B13 rs72613567 allele acted as a protective factor against progression and promoted regression. A polygenic risk score (PRS), based on three single nucleotide polymorphisms, comprising the sum of the three risk alleles, independently predicted histological progression. Conversely, the PRS of the three non-risk alleles was associated with histological regression. Non-genetic factors such as age, sex, BMI changes, and type 2 diabetes mellitus significantly modified the impact of both single genetic variants and the PRS on histology. These findings underscore the necessity of considering these multifaceted interactions for personalized MASLD management, including risk stratification and future therapeutic development.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Vilar-Gomez E, Yates KP, Kleiner DE, et al. Genetic and non-genetic drivers of histological progression and regression in MASLD. J Hepatol. 2025. PMID: 40998180. doi:10.1016/j.jhep.2025.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。